Rimegepant is a calcitonin gene-related peptide (CGRP) receptor blocker used for the acute treatment of migraine, with or without aura, in adults. It is also indicated for the preventive treatment of episodic migraine in adult patients.

According to the widely accepted theory of migraine pathophysiology, dysfunction within the central nervous system, particularly involving the trigeminal ganglion, is considered a key factor in migraine development. When the trigeminal ganglion becomes activated, it stimulates trigeminal afferent nerves that extend to the spinal cord and connect with several pain-sensitive intracranial and extracranial structures, including the dura mater. These pain signals are then carried through second-order ascending neurons to the brainstem, hypothalamus, thalamic nuclei, and eventually to various cortical areas such as the auditory, visual, and motor cortices. The trigeminal ganglion plays an important role in increasing and sustaining migraine headache pain by activating perivascular fibers and releasing pain-related substances such as calcitonin gene-related peptide (CGRP).

The alpha form of CGRP, which is present in primary sensory neurons, is a powerful vasodilator and is strongly linked to migraine pathogenesis. During migraine attacks, CGRP levels rise significantly and return to normal after treatment with triptan medicines. Intravenous administration of CGRP has also been shown to cause migraine-like headaches in patients with migraine. In addition to widening blood vessels, CGRP also acts as a pronociceptive mediator by increasing neuronal excitability and enhancing pain sensitivity.

Rimegepant works by blocking the calcitonin gene-related peptide receptor. It competes with CGRP for receptor binding and prevents CGRP from exerting its effects. This helps reduce the amplification and persistence of migraine headache pain and ultimately helps relieve the headache.

Acute Treatment of Migraine: The recommended dose of Rimegepant is 75 mg taken orally, as needed. The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established.

Preventive Treatment of Episodic Migraine: The recommended dose of Rimegepant is 75 mg taken orally every alternate day.

CYP3A4 Inhibitors: Taking Rimegepant together with strong CYP3A4 inhibitors can greatly increase the level of Rimegepant in the body. Therefore, concurrent use with strong CYP3A4 inhibitors should be avoided. When used with moderate CYP3A4 inhibitors, Rimegepant exposure may also increase. In such cases, another dose of Rimegepant should not be taken within 48 hours.

CYP3A Inducers: Using Rimegepant with strong or moderate CYP3A inducers may significantly reduce the amount of Rimegepant in the body, which can decrease its effectiveness. Concurrent use with strong or moderate CYP3A inducers should be avoided.

P-gp Inhibitors: Co-administration of Rimegepant with strong P-gp inhibitors (such as amiodarone, cyclosporine, lapatinib, quinidine, and ranolazine) may increase Rimegepant levels in the body. Another dose of Rimegepant should be avoided within 48 hours when taken with potent P-gp inhibitors.

Rimegepant is contraindicated in patients with known hypersensitivity to rimegepant, Sylvia ODT, or any of its ingredients.

Allergic reactions such as breathing difficulty and skin rash may occur after taking Rimegepant. The most commonly reported side effects include nausea, abdominal discomfort, and indigestion.

There is not enough information available regarding the developmental risk of using Rimegepant during pregnancy. There are also no sufficient data about the presence of rimegepant or its metabolites in breast milk, its effects on breastfed infants, or its effect on milk production.

Hypersensitivity reactions, including shortness of breath and rash, have been reported with Rimegepant during clinical studies. These reactions may occur even several days after administration, and delayed serious hypersensitivity reactions may also happen. If any hypersensitivity reaction occurs, Rimegepant should be stopped immediately and appropriate treatment should be started.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Pharmacokinetic studies showed no significant difference between elderly and younger adults. However, clinical studies did not include enough patients aged 65 years and older to determine whether their response differs from younger individuals.

Hepatic Impairment: No dose adjustment is needed in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) liver impairment. However, plasma levels of Rimegepant are significantly higher in severe hepatic impairment (Child-Pugh C), so use should be avoided in these patients.

Renal Impairment: No dose adjustment is needed in mild, moderate, or severe renal impairment. However, Rimegepant has not been adequately studied in patients with end-stage renal disease or those receiving dialysis. It should be avoided in patients with end-stage renal disease (CrCl <15 mL/min).

There is limited experience regarding overdose with Rimegepant. In case of overdose, treatment should include general supportive care, close monitoring of vital signs, and observation of the patient's clinical condition. No specific antidote is available for Rimegepant overdose. Due to high protein binding in the blood, dialysis is unlikely to remove significant amounts of the drug.

Store below 25°C, protected from light and moisture. Keep out of reach of children.